



Important update

ONCE-WEEKLY
OZEMPIC[®]
semaglutide injection

Important TGA update: Ozempic[®] supply shortage resolved

Dear Healthcare Professional,

We are writing to inform you that the Therapeutic Goods Administration (TGA) has removed Ozempic[®] (semaglutide) from its medicines shortage list, effective 18 July 2025. Ozempic[®] is indicated for the treatment of type 2 diabetes.¹

In accordance with the updated TGA guidance, prescribers can now resume new patient initiations for Ozempic[®]. You can visit the TGA website for the latest guidance: [tga.gov.au](https://www.tga.gov.au).

The resolved supply shortage is part of our continued commitment to supporting diabetes patients who rely on our medicine.

Should you have any questions, please contact our Medical Information Team at 1800 668 626 or aunrccc@novonordisk.com.

Warm regards,

Dr Ana Svensson
Vice President, Clinical, Medical, Reg & PV
Novo Nordisk Oceania



This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PBS Information: Type 2 diabetes. Criteria Apply. Authority Required
(TELEPHONE/ONLINE FOR FIRST SCRIPT; STREAMLINED FOR SUBSEQUENT SCRIPT).

Refer to PBS Schedule for full Authority Required Information.

Please review full PI before prescribing. Full PI is available at
rss.medsinfo.com.au/no/pi.cfm?product=nopozemp.

Reference: 1. Ozempic® (semaglutide) Approved Product Information. Available at:
rss.medsinfo.com.au/no/pi.cfm?product=nopozemp.

Novo Nordisk Pharmaceuticals Pty Ltd. Level 10, 118 Mount Street, North Sydney NSW 2060. ABN 40 002 879 996. Novo Nordisk Medical Information (Australia) 1800 668 626. www.novonordisk.com.au.
® Registered trademark of Novo Nordisk A/S. AU25OZM00097. July 2025.